Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Immunogenicity and Safety of 10-valent Pneumococcal Nontypeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Administered to Children With Sickle Cell Disease Between 8 Weeks and 2 Years of Age: A Phase III, Open, Controlled Study
source: The Pediatric Infectious Disease Journal
year: 2017
authors: Sirima SB, Tiono A, Gansané Z, Siribié M, Zongo A, Ouédraogo A, François N, Strezova A, Dobbelaere K, Borys D.
summary/abstract:BACKGROUND:
Immunogenicity, safety and reactogenicity of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) were evaluated in children with sickle cell disease (SCD), who are at increased risk for infections.
METHODS:
In this phase III, open-label, single-center, controlled study in Burkina Faso (NCT01175083), children with SCD (S) or without SCD (NS) were assigned to 6 groups (N = 300): children 8-11 weeks of age ( RESULTS:
One month postprimary vaccination, for each vaccine serotype ≥98% of infants in the CONCLUSIONS:
PHiD-CV was immunogenic with an acceptable safety profile in children with and without SCD starting vaccination at 8 weeks to 23 months of age.
DOI: 10.1097/INF.0000000000001518
read more full text
+myBinderRelated Content
-
Long-term opioids may not be best pain management option for all sickle cell patientsSmall study shows some on opioids report...
-
The role of nutrition in the pathophysiology and management of sickle cell disease among children: A review of liter...Sickle cell disease (SCD) is one of the ...
-
sicklecell101Pins from sicklecell101 on Pinterest...
-
Emmaus Life Sciences, Inc. to present results of phase 3 study of endariTM (L-glutamine oral powder) at 59th America...Emmaus will present results of a Phase 3...
-
8 Tips to Support Students With Sickle Cell DiseaseIn the United States, sickle cell diseas...
-
Lab-Grown Blood: What Is It, and How Could It Be Useful?Sometimes a person may have a blood diso...
-
Blood Transfusions: How, Why, and When? (Part 1)https://www.youtube.com/watch?v=KRjjp0Jw...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.